References
- Personal communication to Merck Global Medical Information and Operations Department. October 25, 2012.
- Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Giffin SL. 2009 Annual Report of the American Association of Poison Control Centers’ National Poison Data System (NPDS): 27th Annual Report. Clini Toxicol 2010; 48:979–1178.
- Black Widow Antivenin (Latrodectus mactans). Drug Shortage Bulletin. American Society of Health-System Pharmacy. Available at http://www.ashp.org/drugshortages/current/bulletin.aspx?id = 670. Accessed October 28, 2011.
- Antivenin (Lactrodectus mactans) (Black widow spider antivenin), Merck & Co, Inc., Available at: http://www.merck.com/product/usa/pi_circulars/a/antivenin/antivenin_pi.pdf. Accessed June 12, 2011.
- Clark RF, Wethern-Kestner S, Vance MV, Gerkin R. Clinical presentation and treatment of black widow spider envenomation: a review of 163 cases. Ann Emerg Med 1992; 21:782–787.
- Pneumatikos IA, Galiatsou E, Goe D, Kitsakos A, Nakos G, Vougioklakis TG. Acute fatal toxic myocarditis after black widow spider envenomation. Ann Emerg Med 2003; 41:158.
- Gonzalez Valverde FM, Gomez Ramos MJ, Menarguez Pina F, Vasquez Rojas JL. Fatal latrodectism in an elderly man. Med Clin (Barc) 2001; 117:319.
- Hoyte CO, Cushing TA, Heard KJ. Anaphylaxis to black widow spider antivenom. Am J Emerg Med 2011 Jun 2. [Epub ahead of print].
- Gold BS, Dart RC, Barish RA. Bites of venomous snakes. New Engl J Med 2002; 347:347–356.
- Latrodectus mactans antivenin. Average wholesale price. McKesson Connect. http://www.mckesson.com/en_us/McKesson.com/For%2B Pharmacies/Inpatient/Pharmacy%2BAutomation/Connect-Rx.html. Accessed October 27, 2011.
- Diaz JH, Leblanc KE. Common spider bites. Am Fam Physician 2007; 75:869–873.
- Henkel AW, Sankaranarayanan S. Mechanisms of alpha-latrotoxin action. Cell Tissue Res 1999; 296:229–233.
- O’Malley GF, Dart RC, Kuffner EF. Succesful treatment of lactrodectism with antivenin after 90 hours. N Engl J Med 1999; 340:657.
- Suntorntham S, Roberts JR, Nilsen GJ. Dramatic clinical response to the delayed administration of black widow spider antivenin. Ann Emerg Med 1994; 24:1198–1199.
- Clark RF. The safety and efficacy of antivenin Lactrodectus mactans. Clin Toxicol 2011; 39:125–127.
- Red Back Spider antivenom (Latrodectus hasselti). CSL Group. Available at http://www.csl.com.au/s1/cs/auhq/1217017237558/Web_Product_C/1196562644318/ProductDetail.htm. Accessed October 24, 2011.
- Graudins A, Padula M, Broady K, Nicholson GM. Red-back spider (latrodectus hasselti) antivenom prevents the toxicity of widow spider venoms. Ann Emerg Med 2001; 37:154–160.
- Daly FF, Hill RE, Bogdan GM, Dart RC. Neutralization of Latrodectus mactans and L. hesperus venom by redback spider (L. hasseltii) antivenom. J Toxicol Clin Toxicol 2001; 39(2):119–123.
- Black Widow Spider Antivenin for Patients With Systemic Latrodectism (BWS P3). Accessed at: http://clinicaltrials.gov/ct2/show/NCT00657540. October 24, 2011.
- Clark RF, McKinney PE, Chase PB, Walter FG. Immediate and delayed allergic reactions to Crotalidae polyvalent immune Fab (ovine) antivenom. Ann Emerg Med 2002; 39(6):671–676.
- Personal communication to Instituto Bioclon, Medical Director. September 15, 2011.
- Lai MW, Klein-Schwartz W, Rodgers GC, Abrams JY, Haber DA, Bronstein AV, . Annual report of the American Association of Poison Control Centers’ national poisoning and exposure database. Clin Toxicol 2006; 44:803–932.